Amgen Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 12/06/2023
Amgen Inc Stock Forecast and Price Target
Amgen Inc's most recent price target of $287.00 for 2023 was provided by eleven renowned analysts over the past few months, with an average prediction of $287.00. If this prediction is correct, Amgen Inc's stock could rise by 6.55 percent from its current trading price. The potential increase for the stock is $287.00 per share, with a possible range of $185.00 to $336.00. If you are interested in AMGN stock, you should also look at its competitors.
6.55% Upside
Amgen Inc Fair Value Forecast for 2023 - 2025 - 2030
Amgen Inc's Price has increased by 19.37% In the last three years, going from $204.81 to $244.48. In the next year, analysts expect Fair Value to reach $266.04 – an increase of 8.82%. For the next eight years, the forecast is for Fair Value to grow by 36.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$146.38 | Buy/Sell | $167.35 | 14.09% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$79.36 | Buy/Sell | $90.39 | 14.04% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
15
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$233.87 | Buy/Sell | $322.44 | 32.98% |
| BMRN Stock Forecast | BioMarin Pharmaceutical Inc | Outperform |
10
|
$94.16 | Buy/Sell | $115.79 | 15.21% |
Amgen Inc Revenue Forecast for 2023 - 2025 - 2030
Amgen Inc's Revenue has increased by 12.67% In the last three years, going from $23.36B to $26.32B. In the next year, analysts expect Revenue to reach $27.32B – an increase of 3.78%. For the next eight years, the forecast is for Revenue to grow by 6.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte Corp | Outperform |
9
|
$55.42 | Buy/Sell | $83.59 | 47.96% |
| EXEL Stock Forecast | Exelixis Inc | Outperform |
16
|
$21.93 | Buy/Sell | $25.02 | 23.12% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
.jpg)
Amgen Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Dividend per Share has grown, increasing from $5.80 to $7.76 – a growth of 33.79%. The next year looks promising for Amgen Inc, with analysts predicting Dividend per Share of $8.28 – an increase of 6.70%. Over the next eight years, experts anticipate that Amgen Inc's Dividend per Share will grow at a rate of 62.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$72.42 | Buy/Sell | $119.23 | 17.37% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$21.38 | Buy/Sell | $29.50 | 59.03% |
Amgen Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Free Cash Flow has grown from $8.53B to $9.11B – a 6.81% increase. Next year, analysts are expecting Free Cash Flow to reach $10.40B – an increase of 14.11%. Over the next eight years, the forecast is for Free Cash Flow to grow by 34.60%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$11.02 | Buy/Sell | $17.90 | 76.95% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.79 | Buy/Sell | $56.62 | 126.99% |
Amgen Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's Net Income has seen a drop from $7.84B to $6.55B – a 16.45% decrease. For the next year, analysts are expecting Net Income to reach $10.25B – an increase of 56.44%. Over the next eight years, experts predict that Net Income will grow by 50.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | Buy |
8
|
$20.86 | Buy/Sell | $24.82 | 15.05% |
| DVAX Stock Forecast | Dynavax Technologies | Buy |
11
|
$13.40 | Buy/Sell | $25.00 | 86.57% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$17.24 | Buy/Sell | $34.00 | 103.02% |
Amgen Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's EBITDA has grown by 14.72%, rising from $11.76B to $13.49B. For next year, analysts predict EBITDA of $16.28B, which would mean an increase of 20.70%. Professionals believe that By 2030, Amgen Inc's EBITDA will fall to $13.09B – a 2.94% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$31.60 | Buy/Sell | $63.29 | 115.19% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$33.62 | Buy/Sell | $42.58 | 27.90% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$6.38 | Buy/Sell | $20.42 | 197.81% |
Amgen Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Amgen Inc's EBIT has grown by 3.58%, rising from $9.72B to $10.07B. For next year, analysts predict EBIT of $13.01B, which would mean an increase of 29.19%. Over the next eight years, experts predict that Amgen Inc's EBIT will grow at a rate of 26.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$22.55 | Buy/Sell | $53.75 | 72.95% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$5.51 | Buy/Sell | $15.20 | 99.64% |
| SAGE Stock Forecast | Sage Therapeutics | Hold |
6
|
$20.85 | Buy/Sell | $25.28 | 5.52% |
Amgen Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
Amgen Inc's EPS has increased by 19.37% In the last three years, going from $14.82 to $17.69. In the next year, analysts expect EPS to reach $19.25 – an increase of 8.82%. For the next eight years, the forecast is for EPS to grow by 36.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$5.14 | Buy/Sell | $9.64 | 94.55% |
| XNCR Stock Forecast | Xencor | Buy |
6
|
$19.26 | Buy/Sell | $39.71 | 89.51% |
| MNKD Stock Forecast | MannKind | Buy |
10
|
$3.59 | Buy/Sell | $6.92 | 88.02% |
.jpg)